Furthermore, our work provides a rationale for the development of small molecule inhibitors targeting YTHDC1 as a therapeutic strategy to treat breast cancer and other cancers reliant on YTHDC1 such as AML, endometrial cancer, and glioblastoma. Here, YTHDC1 is linked to breast carcinoma.